Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(3 citation statements)
references
References 21 publications
0
3
0
Order By: Relevance
“…For each donor/replicate, OD was smoothened using a sliding window of size 21, followed by interpolation to obtain OD values for timepoints separated by an interval of 0.1 hrs (6 minutes) starting from the 24 hr timepoint. Specific oxygen consumption rates were computed from the difference equation ( 7) based on the ODE in (6).…”
Section: Estimating Cell Numbers From Optical Densitymentioning
confidence: 99%
See 1 more Smart Citation
“…For each donor/replicate, OD was smoothened using a sliding window of size 21, followed by interpolation to obtain OD values for timepoints separated by an interval of 0.1 hrs (6 minutes) starting from the 24 hr timepoint. Specific oxygen consumption rates were computed from the difference equation ( 7) based on the ODE in (6).…”
Section: Estimating Cell Numbers From Optical Densitymentioning
confidence: 99%
“…The CAR T cells are then expanded to clinical dosages, which can take 7 to 14 days, before final formulation, cryopreservation and subsequent thawing for patient infusion 3,4 . Current commercial CAR T cell therapies largely rely on a centralized manufacturing model, but low manufacturing throughputs and long turnaround times of 21 to 37 days have hindered patient accessibility and treatment efficacy [4][5][6][7][8] . There is thus a need to intensify the scaling-out of autologous CAR T cell production, in order to reduce the wait times and cost of goods of these living drugs 3,9,10 .…”
Section: Introductionmentioning
confidence: 99%
“…7 Similarly, an analysis that estimated the value of reducing wait times for CAR-T treatment using data from the trial JULIET reported that of 167 patients included in the analysis, 52 patients did not receive CAR-T for reasons including death and dropouts due to manufacturing delays. 8 In a study surveying CAR-T treatment centers across the United States, only 25% of patients were reported to receive CAR-T therapy, with a median time patients spent on wait lists being 6 months. 9 Although there is a paucity of real-word data given the relatively recent approval of CAR-T therapies, it is reasonable to conclude that this trend in which a subset of patients cannot access CAR-T treatment despite their eligibility as seen in clinical trials may translate to the real world as well.…”
Section: Introductionmentioning
confidence: 99%